Ventricular arrhythmias following continuous-flow left ventricular assist device implantation: A systematic review.

ABSTRACT

Ventricular arrhythmias (VA) are not uncommon after continuous-flow left ventricular assist device (CF-LVAD) implantation. In this systematic review, we sought to identify the patterns of VA that occurred following CF-LVAD implantation and evaluate their outcomes. An electronic search was performed to identify all articles reporting the development of VA following CF-LVAD implantation. VA was defined as any episode of ventricular fibrillation (VF) or sustained (>30 seconds) ventricular tachycardia (VT). Eleven studies were pooled for the analysis that included 393 CF-LVAD patients with VA. The mean patient age was 57 years [95%CI 54; 61] and 82% [95%CI 73; 88] were male. Overall, 37% [95%CI 19; 60] of patients experienced a new onset VA after CF-LVAD implantation, while 60% [95%CI 51; 69] of patients had a prior history of VA. Overall, 88% of patients [95%CI 78; 94] were supported on HeartMate II CF-LVAD, 6% [95%CI 3; 14] on HeartWare HVAD, and 6% [95%CI 2; 13] on other CF-LVADs. VA was symptomatic in 47% [95%CI 28; 68] of patients and in 50% [95%CI 37; 52], early VA (<30 days from CF-LVAD) was observed. The 30-day mortality rate was 7% [95%CI 5; 11]. Mean follow-up was 22.9 months [95%CI 4.8; 40.8], during which 27% [95%CI 17; 39] of patients underwent heart transplantation. In conclusion, approximately a third of patients had new VA following CF-LVAD placement. VA in CF-LVAD patients is often symptomatic, necessitates treatment, and carries a worse prognosis.